Beijing Chunlizhengda Medical Instruments Co., Ltd. (Stock Code: 1858) has released an announcement detailing several proposals to be voted on at its extraordinary general meeting (EGM), scheduled for 19 November 2025. The meeting will take place concurrently with the class meetings for holders of A shares and H shares at the Company’s headquarters in Tongzhou District, Beijing.
The Company proposes amendments to its Articles of Association and relevant corporate governance rules, including abolishing the Supervisory Committee and transferring relevant functions to the newly established audit committee. The EGM will also consider amendments to internal management policies, specifically the Working System for Independent Directors and Management Measures for Use of Proceeds.
In the same announcement, the Board presented the 2025 Third Quarterly Profit Distribution Plan. With net profit of approximately RMB191.53 million for the first three quarters, the Company intends to pay a cash dividend of RMB2.10 (tax inclusive) for every 10 shares, totalling around RMB80.26 million. The final amount and related exchange rate arrangements will be confirmed upon approval at the EGM.
Shareholders are advised that, if approved, the planned dividend is expected to be distributed on or before 19 January 2026. The announcements also outline procedures for shareholders wishing to attend and the relevant proxy arrangements. The full set of documents, including resolutions and notices for the meetings, is available on the Company’s website and stock exchange platforms. Given the significance of these proposals, shareholders are encouraged to review the circular and attend or vote by proxy in accordance with the provided instructions.